Drug Patents owned by Tg Theraps
1. Drug name - UKONIQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
| US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
| US9969740 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(12 years from now) | |
| US10414773 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(12 years from now) | |
| CN104470923A | TG THERAPS | Selective Pi3K Inhibitor |
Jul, 2033
(10 years from now) | |
| CN104470923B | TG THERAPS | Selective Pi3K Inhibitor |
Jul, 2033
(10 years from now) | |
| CN106661030B | TG THERAPS | Improved Form For Pharmaceutical Preparation Of Pi3K Inhibitors |
May, 2035
(12 years from now) | |
| CN106661030A | TG THERAPS | Improved Form For Pi3K Selective Inhibitor In The Pharmaceutical Formulation |
May, 2035
(12 years from now) | |
| IN201500204P4 | TG THERAPS | Selective Pi3K Delta Inhibitors |
Jul, 2033
(10 years from now) | |
| IN358166B | TG THERAPS | Selective Pi3K Delta Inhibitors |
Jul, 2033
(10 years from now) | |
| IN201647042988A | TG THERAPS | Improved Forms Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations |
May, 2035
(12 years from now) | |
| IN328766B | TG THERAPS | Improved Forms Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations |
May, 2035
(12 years from now) | |
| EP2870157B1 | TG THERAPS | Selective Pi3K Delta Inhibitors |
Jul, 2033
(10 years from now) | |
| EP3260455B1 | TG THERAPS | Selective Pi3K Delta Inhibitors |
Jul, 2033
(10 years from now) | |
| EP2870157A1 | TG THERAPS | Selective Pi3K Delta Inhibitors |
Jul, 2033
(10 years from now) | |
| EP3260455A1 | TG THERAPS | Selective Pi3K Delta Inhibitors |
Jul, 2033
(10 years from now) | |
| EP3149000B1 | TG THERAPS | Crystalline Tosylate Salt Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations |
May, 2035
(12 years from now) | |
| EP3149000A1 | TG THERAPS | Crystalline Tosylate Salt Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations |
May, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
| US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
| US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
| US10947244 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(12 years from now) | |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 200MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.